Skip to content
request demo
Trusted by 100+ leading biopharma companies

Find the Clinical Evidence Gaps Your Competitors Haven't Closed.

Ferma's pharma evidence gap analysis maps the clinical evidence landscape across your indication -- identifying where competitors have strong data, where they're exposed, and where your asset has a differentiation opportunity. 

request demo

What the Evidence Gap Analysis Produces

scorecard
Evidence Landscape Map
Structured view of the pharma clinical evidence base across your indication - by asset, endpoint, patient population, and data quality - continuously updated from trials, publications, and medical conferences.
rNPV Valuation Model
Competitor Evidence Package Analysis
Analysis of each competitor's pharma data package: trial design, endpoint selection, patient populations, subgroup data, and label status - identifying where clinical evidence is strong, where it's thin, and where evidence gaps exist for your asset to exploit.
rNPV Valuation Model
Differentiation Opportunity Assessment
Maps your asset's clinical evidence profile against the competitive set in pharma. Highlights where you have a differentiation opportunity, patient population, endpoint, mechanism, safety profile, and where you face headwinds.
Com Lands
Conference Evidence Tracker
Monitors medical conference presentations for competitor evidence updates - new data, updated analyses, subgroup findings - ensuring your pharma evidence gap view stays current after every major congress.

Who Uses Pharma Evidence Gap Analysis

01

Competetive Intelligence

Track how the pharma clinical evidence base in your TA is evolving and where competitors are building differentiation, and surface evidence gaps before they become competitive threats.

02

New Product Planning

Map pharma evidence gaps that inform TPP development, identifying the clinical differentiation attributes that matter most to prescribers and payers.

03

Medical Affairs

Understand the full clinical evidence landscape your MSLs and KOLs navigate, and where your asset's evidence package stands relative to competitors in your indication.

quote

We identified two clinical differentiation opportunities we hadn't seen before. Those gaps are now part of our Phase III endpoint strategy.

Director, Competitive Intelligence & Evidence Strategy
Large Cap Pharma
CTA Home

Know where the evidence gaps are before your competitors close them. 

Request Demo

Frequently Asked Questions

How does Ferma's Evidence Gap Analysis differ from a standard competitive landscape report?

A competitive landscape report gives you a broad overview of all assets in a TA. Ferma's pharma evidence gap analysis is specifically structured around clinical evidence quality, it maps where each competitor's data package is strong, where it's thin, and where your asset has a differentiation opportunity. It incorporates trial design, endpoint selection, patient populations, and conference presentations not just phase and approval status.

Does the Evidence Gap Analysis update automatically as new data is presented?

Yes. Ferma's Conference Coverage Agentic Workflow continuously monitors medical congress presentations for competitor evidence updates - new analyses, subgroup findings, and label expansions. Your pharma evidence gap view updates automatically after every major congress, without requiring a new manual analysis.

Which teams typically use the Evidence Gap Analysis Agentic Workflow?

Primarily Competitive Intelligence, New Product Planning, and Medical Affairs teams at pharma and biotech companies. CI teams use it to track how the pharma clinical evidence base evolves and identify where competitors are building differentiation. NPP teams use it to inform TPP development and clinical positioning strategy. Medical Affairs teams use it to prepare MSLs and KOLs for evidence-based conversations with prescribers and payers.

What is a pharma evidence gap analysis and why does it matter?

A pharma evidence gap analysis maps the clinical evidence base across a therapeutic area, identifying where competitors have strong data packages, where their evidence is thin or absent, and where an asset in development has a clinical or commercial differentiation opportunity. For CI, NPP, and Medical Affairs teams, it answers the question: where in the indication does the current evidence leave room for a better-differentiated product? Ferma's Evidence Gap Analysis Agentic Workflow automates this process - monitoring trials, publications, and medical conferences continuously and producing a structured, cited output your team can use directly in strategy and planning cycles.